Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q4 2017 Earnings Presentation
10 slides from Anika Therapeutics's earnings presentation, Feb 22, 2018
Slide 1: Fourth Quarter 2017 Earnings Call Presentation
Fourth Quarter 2017 Earnings Call Presentation February 22, 2018 NASDAQ: ANIK 0
Slide 2: Safe Harbor Statement
Safe Harbor Statement The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company’s expanded commercial capabilities, product pipeline and associated timelines, upcoming corporate milestones, and growth strate
Slide 3: CINGAL: Commercial and Clinical Trial Update
CINGAL: Commercial and Clinical Trial Update First-in-class single-injection treatment combining FDA- approved HA and steroid for pain associated with Osteoarthritis (OA) Rapid and long-lasting pain relief through 6-months, with a strong safety profile; Potential for 9-month efficacy claim Str
Slide 4: CINGAL: Progress Enrolling 3-Month Extension Study
CINGAL: Progress Enrolling 3-Month Extension Study CINGAL 13-01, a randomized, double-blind, placebo- Continued progress controlled, active comparator Phase III study enrolling patients in the 3- month extension study for CINGAL to collect 9-month efficacy data First Phase III study met all prim
Slide 5: Regenerative Medicine Pipeline Update
Regenerative Medicine Pipeline Update FastTRACK HYALOFAST Product Candidate for Phase III Clinical Trial Rotator Cuff Repair Only HA-Based Scaffold New product candidate Material leveraging Anika’s proprietary Provides a single-step and HYAFF technology cost effective solution to Product pro
Slide 6: Strategic R&D Collaborations
Strategic R&D Collaborations University of Massachusetts Amherst • Collaboration focused on localized injection therapy for the treatment of Rheumatoid Arthritis (RA) • Expansion of original collaboration that began in Q2 2015 University of Liverpool • Collaboration focused on developing an injectab
Slide 7: 2017 Business Milestone Achievements
2017 Business Milestone Achievements Expanded the international presence of CINGAL and MONOVISC, with MONOVISC product approvals and related commercial launches in India, Australia, and Taiwan Completed patient enrollment in the CINGAL Phase III clinical study, and continued progress enrolling patie
Slide 8: 2018 Strategic Initiatives to Drive Sustained Growth and Create Shareholder Value
2018 Strategic Initiatives to Drive Sustained Growth and Create Shareholder Value Executing all Global commercial activities leading to expansion driven by the FDA approval growth of CINGAL of CINGAL and MONOVISC 2018 Advancing our Building the direct orthobiologics & commercialization regenerative
Slide 9: Q4 & FY 2017 Financial Highlights
Q4 & FY 2017 Financial Highlights Q4 2017 TOTAL REVENUE MONOVISC REVENUE INTERNATIONAL 21% ORTHOBIOLOGICS $157M $29.4M YEAR-OVER-YEAR IN Q4 2017 Full Year 2017 22% REVENUE GROWTH CASH & INVESTMENTS AS OF DECEMBER 31, 2017; NO DEBT 10% 75% $31.8M $2.11 Total Revenue Product Growth Gross Margin Net In
Slide 10: Q&A
Q&A Fourth Quarter 2017 Earnings Call Presentation February 22, 2018 NASDAQ: ANIK 9